Our mission is to discover and develop better medicines for patients with autoimmune and inflammatory disease.
Octagon believes that patients with severe autoimmunity deserve better treatment options.
Existing medicines compromise healthy immune functioning, putting those with autoimmune disorders at increased risk of infection and some cancers. As a result, most of these treatments can only be used for a limited duration. Octagon has shown that the immune cells that cause these disorders are metabolically distinct from healthy immune cells. Octagon’s first product is a monoclonal antibody that restores the endogenous activity of a key immune regulatory receptor, enabling rebalancing of the immune system while sparing beneficial immune functioning. This will be an ideal maintenance therapy for patients dealing with chronic autoimmune conditions.
Octagon leverages insights into immune cell metabolism to precisely treat disease.
Contact us to learn more about discovery partnership opportunities.